PDCD4 is an androgen-repressed tumor suppressor that regulates prostate cancer growth and castration resistance

Kenji Zennami, Su Mi Choi, Ross Liao, Ying Li, Wikum Dinalankara, Luigi Marchionni, Fatema H. Rafiqi, Akira Kurozumi, Koji Hatano, Shawn Lupold

Research output: Contribution to journalArticle

Abstract

Androgen receptor (AR) transcriptional activity contributes to prostate cancer development and castration resistance. The growth and survival pathways driven by AR remain incompletely defined. Here, we found PDCD4 to be a new target of AR signaling and a potent regulator of prostate cancer cell growth, survival, and castration resistance. The 3' untranslated region of PDCD4 is directly targeted by the androgen-induced miRNA, miR-21. Androgen treatment suppressed PDCD4 expression in a dose responsive and miR-21-dependent manner. Correspondingly, AR inhibition dose-responsively induced PDCD4 expression. Using data from prostate cancer tissue samples in The Cancer Genome Atlas (TCGA), we found a significant and inverse correlation between miR-21 and PDCD4 mRNA and protein levels. Higher Gleason grade tumors exhibited significantly higher levels of miR-21 and significantly lower levels of PDCD4 mRNA and protein. PDCD4 knockdown enhanced androgen-dependent cell proliferation and cell-cycle progression, inhibited apoptosis, and was sufficient to drive androgen-independent growth. On the other hand, PDCD4 overexpression inhibited miR-21- mediated growth and androgen independence. The stable knockdown of PDCD4 in androgen-dependent prostate cancer cells enhanced subcutaneous tumor take rate in vivo, accelerated tumor growth, and was sufficient for castrationresistant tumor growth. Implications: This study provides the first evidence that PDCD4 is an androgen-suppressed protein capable of regulating prostate cancer cell proliferation, apoptosis, and castration resistance. These results uncover miR-21 and PDCD4-regulated pathways as potential new targets for castration-resistant prostate cancer.

Original languageEnglish (US)
Pages (from-to)618-627
Number of pages10
JournalMolecular Cancer Research
Volume17
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Castration
Androgens
Prostatic Neoplasms
Androgen Receptors
Growth
Neoplasms
Cell Proliferation
Apoptosis
Messenger RNA
Proteins
Atlases
3' Untranslated Regions
MicroRNAs
Cell Survival
Cell Cycle
Genome

ASJC Scopus subject areas

  • Molecular Biology
  • Oncology
  • Cancer Research

Cite this

PDCD4 is an androgen-repressed tumor suppressor that regulates prostate cancer growth and castration resistance. / Zennami, Kenji; Choi, Su Mi; Liao, Ross; Li, Ying; Dinalankara, Wikum; Marchionni, Luigi; Rafiqi, Fatema H.; Kurozumi, Akira; Hatano, Koji; Lupold, Shawn.

In: Molecular Cancer Research, Vol. 17, No. 2, 01.02.2019, p. 618-627.

Research output: Contribution to journalArticle

Zennami, Kenji ; Choi, Su Mi ; Liao, Ross ; Li, Ying ; Dinalankara, Wikum ; Marchionni, Luigi ; Rafiqi, Fatema H. ; Kurozumi, Akira ; Hatano, Koji ; Lupold, Shawn. / PDCD4 is an androgen-repressed tumor suppressor that regulates prostate cancer growth and castration resistance. In: Molecular Cancer Research. 2019 ; Vol. 17, No. 2. pp. 618-627.
@article{187cacce5aa04557b25e2a26ef299f80,
title = "PDCD4 is an androgen-repressed tumor suppressor that regulates prostate cancer growth and castration resistance",
abstract = "Androgen receptor (AR) transcriptional activity contributes to prostate cancer development and castration resistance. The growth and survival pathways driven by AR remain incompletely defined. Here, we found PDCD4 to be a new target of AR signaling and a potent regulator of prostate cancer cell growth, survival, and castration resistance. The 3' untranslated region of PDCD4 is directly targeted by the androgen-induced miRNA, miR-21. Androgen treatment suppressed PDCD4 expression in a dose responsive and miR-21-dependent manner. Correspondingly, AR inhibition dose-responsively induced PDCD4 expression. Using data from prostate cancer tissue samples in The Cancer Genome Atlas (TCGA), we found a significant and inverse correlation between miR-21 and PDCD4 mRNA and protein levels. Higher Gleason grade tumors exhibited significantly higher levels of miR-21 and significantly lower levels of PDCD4 mRNA and protein. PDCD4 knockdown enhanced androgen-dependent cell proliferation and cell-cycle progression, inhibited apoptosis, and was sufficient to drive androgen-independent growth. On the other hand, PDCD4 overexpression inhibited miR-21- mediated growth and androgen independence. The stable knockdown of PDCD4 in androgen-dependent prostate cancer cells enhanced subcutaneous tumor take rate in vivo, accelerated tumor growth, and was sufficient for castrationresistant tumor growth. Implications: This study provides the first evidence that PDCD4 is an androgen-suppressed protein capable of regulating prostate cancer cell proliferation, apoptosis, and castration resistance. These results uncover miR-21 and PDCD4-regulated pathways as potential new targets for castration-resistant prostate cancer.",
author = "Kenji Zennami and Choi, {Su Mi} and Ross Liao and Ying Li and Wikum Dinalankara and Luigi Marchionni and Rafiqi, {Fatema H.} and Akira Kurozumi and Koji Hatano and Shawn Lupold",
year = "2019",
month = "2",
day = "1",
doi = "10.1158/1541-7786.MCR-18-0837",
language = "English (US)",
volume = "17",
pages = "618--627",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - PDCD4 is an androgen-repressed tumor suppressor that regulates prostate cancer growth and castration resistance

AU - Zennami, Kenji

AU - Choi, Su Mi

AU - Liao, Ross

AU - Li, Ying

AU - Dinalankara, Wikum

AU - Marchionni, Luigi

AU - Rafiqi, Fatema H.

AU - Kurozumi, Akira

AU - Hatano, Koji

AU - Lupold, Shawn

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Androgen receptor (AR) transcriptional activity contributes to prostate cancer development and castration resistance. The growth and survival pathways driven by AR remain incompletely defined. Here, we found PDCD4 to be a new target of AR signaling and a potent regulator of prostate cancer cell growth, survival, and castration resistance. The 3' untranslated region of PDCD4 is directly targeted by the androgen-induced miRNA, miR-21. Androgen treatment suppressed PDCD4 expression in a dose responsive and miR-21-dependent manner. Correspondingly, AR inhibition dose-responsively induced PDCD4 expression. Using data from prostate cancer tissue samples in The Cancer Genome Atlas (TCGA), we found a significant and inverse correlation between miR-21 and PDCD4 mRNA and protein levels. Higher Gleason grade tumors exhibited significantly higher levels of miR-21 and significantly lower levels of PDCD4 mRNA and protein. PDCD4 knockdown enhanced androgen-dependent cell proliferation and cell-cycle progression, inhibited apoptosis, and was sufficient to drive androgen-independent growth. On the other hand, PDCD4 overexpression inhibited miR-21- mediated growth and androgen independence. The stable knockdown of PDCD4 in androgen-dependent prostate cancer cells enhanced subcutaneous tumor take rate in vivo, accelerated tumor growth, and was sufficient for castrationresistant tumor growth. Implications: This study provides the first evidence that PDCD4 is an androgen-suppressed protein capable of regulating prostate cancer cell proliferation, apoptosis, and castration resistance. These results uncover miR-21 and PDCD4-regulated pathways as potential new targets for castration-resistant prostate cancer.

AB - Androgen receptor (AR) transcriptional activity contributes to prostate cancer development and castration resistance. The growth and survival pathways driven by AR remain incompletely defined. Here, we found PDCD4 to be a new target of AR signaling and a potent regulator of prostate cancer cell growth, survival, and castration resistance. The 3' untranslated region of PDCD4 is directly targeted by the androgen-induced miRNA, miR-21. Androgen treatment suppressed PDCD4 expression in a dose responsive and miR-21-dependent manner. Correspondingly, AR inhibition dose-responsively induced PDCD4 expression. Using data from prostate cancer tissue samples in The Cancer Genome Atlas (TCGA), we found a significant and inverse correlation between miR-21 and PDCD4 mRNA and protein levels. Higher Gleason grade tumors exhibited significantly higher levels of miR-21 and significantly lower levels of PDCD4 mRNA and protein. PDCD4 knockdown enhanced androgen-dependent cell proliferation and cell-cycle progression, inhibited apoptosis, and was sufficient to drive androgen-independent growth. On the other hand, PDCD4 overexpression inhibited miR-21- mediated growth and androgen independence. The stable knockdown of PDCD4 in androgen-dependent prostate cancer cells enhanced subcutaneous tumor take rate in vivo, accelerated tumor growth, and was sufficient for castrationresistant tumor growth. Implications: This study provides the first evidence that PDCD4 is an androgen-suppressed protein capable of regulating prostate cancer cell proliferation, apoptosis, and castration resistance. These results uncover miR-21 and PDCD4-regulated pathways as potential new targets for castration-resistant prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=85060960672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060960672&partnerID=8YFLogxK

U2 - 10.1158/1541-7786.MCR-18-0837

DO - 10.1158/1541-7786.MCR-18-0837

M3 - Article

C2 - 30518628

AN - SCOPUS:85060960672

VL - 17

SP - 618

EP - 627

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 2

ER -